List of works - Zofia Mazerska

Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells

scientific article published on 19 August 2020

Binary Mixtures of Selected Bisphenols in the Environment: Their Toxicity in Relationship to Individual Constituents

article

CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells.

scientific article

CYP3A4-dependent cellular response does not relate to CYP3A4-catalysed metabolites of C-1748 and C-1305 acridine antitumor agents in HepG2 cells

scientific article

Cytochrome P450 isoenzymes in metabolism of endo- and exogenic compounds

scientific article published in January 2009

Design, synthesis and high antitumor potential of new unsymmetrical bisacridine derivatives towards human solid tumors, specifically pancreatic cancers and their unique ability to stabilize DNA G-quadruplexes

scientific article published on 16 July 2020

Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells

scientific article published on 06 April 2012

Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7

scientific article published on 22 March 2018

Electroanalytical and spectroscopic procedures for examination of interactions between double stranded DNA and intercalating drugs.

scientific article published on 17 October 2007

Electrochemical and in silico approaches for liver metabolic oxidation of antitumor-active triazoloacridinone C-1305

scientific article published on 23 March 2020

Electrochemical simulation of metabolism for antitumor-active imidazoacridinone C-1311 and in silico prediction of drug metabolic reactions

scientific article published on 09 March 2019

Electrooxidation of dissolved dsDNA backed by in situ UV-Vis spectroscopy

scientific article published on 08 July 2006

Enhanced Activity of P4503A4 and UGT1A10 Induced by Acridinone Derivatives C-1305 and C-1311 in MCF-7 and HCT116 Cancer Cells: Consequences for the Drugs' Cytotoxicity, Metabolism and Cellular Response

scientific article published on 31 May 2020

Enzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA

scientific article published on 01 March 2001

Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells

scientific article published on 23 August 2011

Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.

scientific article published on 16 March 2016

Improved cytotoxicity and preserved level of cell death induced in colon cancer cells by doxorubicin after its conjugation with iron-oxide magnetic nanoparticles.

scientific article published on 18 February 2016

Influence of temperature and interactions with ligands on dissociation of dsDNA and ligand-dsDNA complexes of various types of binding. An electrochemical study.

scientific article

Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305.

scientific article published on 29 February 2016

Metabolic Profiles of New Unsymmetrical Bisacridine Antitumor Agents in Electrochemical and Enzymatic Noncellular Systems and in Tumor Cells

scientific article published in April 2021

Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.

scientific article published on 16 November 2012

Metabolic transformations of antitumor imidazoacridinone, C-1311, with microsomal fractions of rat and human liver.

scientific article published on 17 December 2007

Modulation of CYP3A4 activity and induction of apoptosis, necrosis and senescence by the anti-tumour imidazoacridinone C-1311 in human hepatoma cells

scientific article published on 14 January 2013

Modulation of UDP-glucuronidation by acridinone antitumor agents C-1305 and C-1311 in HepG2 and HT29 cell lines, despite slight impact in noncellular systems

scientific article published on 22 November 2017

Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311

scientific article published on 01 November 2003

NADPH-cytochrome P450 reductase, not only the partner of cytochrome P450

scientific article published in January 2009

New Unsymmetrical Bisacridine Derivatives Noncovalently Attached to Quaternary Quantum Dots Improve Cancer Therapy by Enhancing Cytotoxicity toward Cancer Cells and Protecting Normal Cells

scientific article published on 01 April 2020

Novel resveratrol-based substrates for human hepatic, renal, and intestinal UDP-glucuronosyltransferases

scientific article published on 11 March 2014

Phase I and phase II metabolism simulation of antitumor-active 2-hydroxyacridinone with electrochemistry coupled on-line with mass spectrometry

article

Polymorphism and the level of P450 gene expression in xenobiotic metabolism

scientific article published in January 2009

Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia.

scientific article published on 18 May 2013

Products of metabolic activation of the antitumor drug ledakrin (nitracrine) in vitro.

scientific article

Progress in targeting tumor cells by using drug-magnetic nanoparticles conjugate.

scientific article published on February 2013

Relationship between volatile organohalogen compounds in drinking water and human urine in Poland.

scientific article published in December 2003

Revision of biological methods for determination of EDC presence and their endocrine potential.

scientific article published on January 2015

Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10

scientific article

Similarity between enzymatic and electrochemical oxidation of 2-hydroxyacridinone, the reference compound of antitumor imidazoacridinones

scientific article published in January 2003

Stable nanoconjugates of transferrin with alloyed quaternary nanocrystals Ag-In-Zn-S as a biological entity for tumor recognition

scientific article published on 01 January 2018

The imidazoacridinone antitumor drug, C-1311, is metabolized by flavin monooxygenases but not by cytochrome P450s

scientific article published on 09 May 2011

The overexpression of CPR and P450 3A4 in pancreatic cancer cells changes the metabolic profile and increases the cytotoxicity and pro-apoptotic activity of acridine antitumor agent, C-1748.

scientific article

The relevance of enzymatic oxidation by horseradish peroxidase to antitumour potency of imidazoacridinone derivatives

scientific article published on 01 August 1998

The role of glucuronidation in drug resistance

scientific article published on 22 January 2016

The synthesis and antitumor activity of N-glycosyl derivatives of daunorubicin

scientific article published on 01 October 1984

UDP-glucuronyltransferases in detoxification and activation metabolism of endogenous compounds and xenobiotics

scientific article published on 01 January 2011

UDP-glucuronyltransferases, proteins of endoplasmic reticulum--structure and mechanism of action

scientific article

Volatile organohalogen compounds in human urine: the effect of environmental exposure

scientific article published on 14 July 2005

List of works by Zofia Mazerska

Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells

Binary Mixtures of Selected Bisphenols in the Environment: Their Toxicity in Relationship to Individual Constituents

CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells.

CYP3A4-dependent cellular response does not relate to CYP3A4-catalysed metabolites of C-1748 and C-1305 acridine antitumor agents in HepG2 cells

Cytochrome P450 isoenzymes in metabolism of endo- and exogenic compounds

Design, synthesis and high antitumor potential of new unsymmetrical bisacridine derivatives towards human solid tumors, specifically pancreatic cancers and their unique ability to stabilize DNA G-quadruplexes

Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells

Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7

Electroanalytical and spectroscopic procedures for examination of interactions between double stranded DNA and intercalating drugs.

Electrochemical and in silico approaches for liver metabolic oxidation of antitumor-active triazoloacridinone C-1305

Electrochemical simulation of metabolism for antitumor-active imidazoacridinone C-1311 and in silico prediction of drug metabolic reactions

Electrooxidation of dissolved dsDNA backed by in situ UV-Vis spectroscopy

Enhanced Activity of P4503A4 and UGT1A10 Induced by Acridinone Derivatives C-1305 and C-1311 in MCF-7 and HCT116 Cancer Cells: Consequences for the Drugs' Cytotoxicity, Metabolism and Cellular Response

Enzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA

Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells

Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.

Improved cytotoxicity and preserved level of cell death induced in colon cancer cells by doxorubicin after its conjugation with iron-oxide magnetic nanoparticles.

Influence of temperature and interactions with ligands on dissociation of dsDNA and ligand-dsDNA complexes of various types of binding. An electrochemical study.

Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305.

Metabolic Profiles of New Unsymmetrical Bisacridine Antitumor Agents in Electrochemical and Enzymatic Noncellular Systems and in Tumor Cells

Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.

Metabolic transformations of antitumor imidazoacridinone, C-1311, with microsomal fractions of rat and human liver.

Modulation of CYP3A4 activity and induction of apoptosis, necrosis and senescence by the anti-tumour imidazoacridinone C-1311 in human hepatoma cells

Modulation of UDP-glucuronidation by acridinone antitumor agents C-1305 and C-1311 in HepG2 and HT29 cell lines, despite slight impact in noncellular systems

Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311

NADPH-cytochrome P450 reductase, not only the partner of cytochrome P450

New Unsymmetrical Bisacridine Derivatives Noncovalently Attached to Quaternary Quantum Dots Improve Cancer Therapy by Enhancing Cytotoxicity toward Cancer Cells and Protecting Normal Cells

Novel resveratrol-based substrates for human hepatic, renal, and intestinal UDP-glucuronosyltransferases

Phase I and phase II metabolism simulation of antitumor-active 2-hydroxyacridinone with electrochemistry coupled on-line with mass spectrometry

Polymorphism and the level of P450 gene expression in xenobiotic metabolism

Pregnane X receptor dependent up-regulation of CYP2C9 and CYP3A4 in tumor cells by antitumor acridine agents, C-1748 and C-1305, selectively diminished under hypoxia.

Products of metabolic activation of the antitumor drug ledakrin (nitracrine) in vitro.

Progress in targeting tumor cells by using drug-magnetic nanoparticles conjugate.

Relationship between volatile organohalogen compounds in drinking water and human urine in Poland.

Revision of biological methods for determination of EDC presence and their endocrine potential.

Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10

Similarity between enzymatic and electrochemical oxidation of 2-hydroxyacridinone, the reference compound of antitumor imidazoacridinones

Stable nanoconjugates of transferrin with alloyed quaternary nanocrystals Ag-In-Zn-S as a biological entity for tumor recognition

The imidazoacridinone antitumor drug, C-1311, is metabolized by flavin monooxygenases but not by cytochrome P450s

The overexpression of CPR and P450 3A4 in pancreatic cancer cells changes the metabolic profile and increases the cytotoxicity and pro-apoptotic activity of acridine antitumor agent, C-1748.

The relevance of enzymatic oxidation by horseradish peroxidase to antitumour potency of imidazoacridinone derivatives

The role of glucuronidation in drug resistance

The synthesis and antitumor activity of N-glycosyl derivatives of daunorubicin

UDP-glucuronyltransferases in detoxification and activation metabolism of endogenous compounds and xenobiotics

UDP-glucuronyltransferases, proteins of endoplasmic reticulum--structure and mechanism of action

Volatile organohalogen compounds in human urine: the effect of environmental exposure

[Glucuronidation of antitumour therapeutics--detoxification, mechanism of resistance or prodrug formation?]